- High-margin licensing royalties of 5-10% of gross sales of its patented bioscience technology and process are an attractive valuation builder; LXRP sees more licensing opportunities in 2018
- LXRP’s technology is patented in the U.S. and Australia; company has national/regional filings pending in 44 countries
Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) generates revenue by out-licensing its patented global technology related to ingestion of edible cannabinoids at a rate of 5-10% of gross sales to its third-party partners. LXRP has also expanded its process of improved and faster inhalation by the body of fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) in pain medications, and even nicotine, a good example of bioabsorption breakthrough technology (http://cnw.fm/DnHZ9). LXRP is now positioned to license its technology to tobacco giants and major drug companies, as well as cannabinoid biopharmaceutical companies.
As a result, LXRP sees new business opportunities in 2018. The company is now positioned to out-license — at a high royalty rate — its intellectual property (IP) to biopharmaceutical companies as a partner rather than a competitor, working with other companies, including cannabinoid edible producers, instead of competing with them.
An R&D-driven company, LXRP is disrupting the global industry by specializing in the ingestion of edible forms of cannabinoids. Its technology and process platform offers more rapid forms of delivery and intestinal absorption of orally-taken cannabinoids, vitamins, nicotine and non-steroidal inflammatory drugs. Its patented process not only improves the body’s absorption of edible cannabinoids; it also masks taste, reduces by roughly 75% the time of onset, and increases bio-absorption by 5-10x. The company has secured patents related to its processing technology in the U.S. and Australia, and it has a portfolio of some 19 national/regional patent application filings in some 44 countries (http://cnw.fm/jW0QP).
Primarily a B2B company, LXRP also makes for demonstration purposes branded consumer products under the ViPova™, Lexaria Energy Foods, and TurboCBD™ brands. It recently acquired the remaining 49% of its majority owned Poviva Tea LLC subsidiary (http://cnw.fm/bPdT2). It now owns 100% ownership interest, reaffirming its commitment to the ViPova product lines, as noted by the company in a recent news release.
Separately, in financial news, LXRP has extended the date of its warrants issued on January 19, 2017, to expire on January 19, 2019. The exercise price and the quantity of the warrants has not changed, it said in a 8K SEC filing. LXRP, in its corporate presentation, said that the next round of capital investment is expected to be in “plant to bloodstream” companies, such as itself.
For more information, visit the company’s website at www.LexariaBioscience.com
More from CanadianCannabisWire
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
For more information please visit https://www.CanadianCannabisWire.com